Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Emergency Department of Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Front Immunol. 2022 Jun 15;13:899140. doi: 10.3389/fimmu.2022.899140. eCollection 2022.
Peritoneal fibrosis contributes to ultrafiltration failure in peritoneal dialysis (PD) patients and thus restricts the wide application of PD in clinic. Recently we have demonstrated that histone deacetylase 6 (HDAC6) is critically implicated in high glucose peritoneal dialysis fluid (HG-PDF) induced peritoneal fibrosis, however, the precise mechanisms of HDAC6 in peritoneal fibrosis have not been elucidated. Here, we focused on the role and mechanisms of HDAC6 in chlorhexidine gluconate (CG) induced peritoneal fibrosis and discussed the mechanisms involved. We found Tubastatin A (TA), a selective inhibitor of HDAC6, significantly prevented the progression of peritoneal fibrosis, as characterized by reduction of epithelial-mesenchymal transition (EMT) and extracellular matrix (ECM) protein deposition. Inhibition of HDAC6 remarkably suppressed the expression of matrix metalloproteinases-2 (MMP2) and MMP-9. Administration of TA also increased the expression of acetylation Histone H3 and acetylation α-tubulin. Moreover, our results revealed that blockade of HDAC6 inhibited alternatively M2 macrophages polarization by suppressing the activation of TGF-β/Smad3, PI3K/AKT, and STAT3, STAT6 pathways. To give a better understanding of the mechanisms, we further established two cell injured models in Raw264.7 cells by using IL-4 and HG-PDF. Our experiments illustrated that both IL-4 and HG-PDF could induce M2 macrophage polarization, as demonstrated by upregulation of CD163 and Arginase-1. Inhibition of HDAC6 by TA significantly abrogated M2 macrophage polarization dose-dependently by suppressing TGF-β/Smad, IL4/STAT6, and PI3K/AKT signaling pathways. Collectively, our study revealed that blockade of HDAC6 by TA could suppress the progression of CG-induced peritoneal fibrosis by blockade of M2 macrophage polarization. Thus, HDAC6 may be a promising target in peritoneal fibrosis treatment.
腹膜纤维化导致腹膜透析(PD)患者超滤失败,从而限制了 PD 在临床中的广泛应用。最近我们已经证明组蛋白去乙酰化酶 6(HDAC6)在高糖腹膜透析液(HG-PDF)诱导的腹膜纤维化中起着至关重要的作用,然而,HDAC6 在腹膜纤维化中的确切机制尚未阐明。在这里,我们专注于 HDAC6 在葡萄糖酸氯己定(CG)诱导的腹膜纤维化中的作用和机制,并讨论了涉及的机制。我们发现,HDAC6 的选择性抑制剂 Tubastatin A(TA)可显著阻止腹膜纤维化的进展,其特征在于上皮间质转化(EMT)和细胞外基质(ECM)蛋白沉积减少。HDAC6 的抑制显著抑制了基质金属蛋白酶-2(MMP2)和 MMP-9 的表达。TA 的给药还增加了乙酰化组蛋白 H3 和乙酰化α-微管蛋白的表达。此外,我们的结果表明,通过抑制 TGF-β/Smad3、PI3K/AKT 和 STAT3、STAT6 通路,HDAC6 的阻断抑制了交替的 M2 巨噬细胞极化。为了更好地理解机制,我们进一步在 Raw264.7 细胞中建立了两种细胞损伤模型,分别使用 IL-4 和 HG-PDF。我们的实验表明,IL-4 和 HG-PDF 均可诱导 M2 巨噬细胞极化,表现在 CD163 和精氨酸酶-1 的上调。TA 对 HDAC6 的抑制通过抑制 TGF-β/Smad、IL4/STAT6 和 PI3K/AKT 信号通路,显著地、剂量依赖性地消除了 M2 巨噬细胞极化。总之,我们的研究表明,TA 通过阻断 M2 巨噬细胞极化抑制 CG 诱导的腹膜纤维化进展。因此,HDAC6 可能是腹膜纤维化治疗的一个有前途的靶点。